Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
F 2.70 -3.23% -0.09
NERV closed down 3.23 percent on Monday, March 18, 2024, on 28 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -3.23%
NR7 Range Contraction -3.23%
NR7-2 Range Contraction -3.23%
Narrow Range Bar Range Contraction -3.23%
Wide Bands Range Expansion -3.23%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 16 hours ago
Outside Day about 16 hours ago
Up 2% about 16 hours ago
Up 1% about 16 hours ago
60 Minute Opening Range Breakdown about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Minerva Neurosciences, Inc Description

Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Parkinson's Disease Psychoactive Drugs Schizophrenia Major Depressive Disorder Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Ketones Treatment Of Major Depressive Disorder Antidepressants Central Nervous System Disease Insomnia Dopamine Investigational New Drug Treatment Of Central Nervous System Diseases

Is NERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.49
52 Week Low 1.56
Average Volume 148,046
200-Day Moving Average 7.13
50-Day Moving Average 6.70
20-Day Moving Average 3.96
10-Day Moving Average 2.72
Average True Range 0.65
RSI (14) 28.06
ADX 45.18
+DI 11.98
-DI 36.82
Chandelier Exit (Long, 3 ATRs) 7.90
Chandelier Exit (Short, 3 ATRs) 4.34
Upper Bollinger Bands 8.38
Lower Bollinger Band -0.46
Percent B (%b) 0.36
BandWidth 223.09
MACD Line -1.34
MACD Signal Line -1.39
MACD Histogram 0.0519
Fundamentals Value
Market Cap 18.88 Million
Num Shares 6.99 Million
EPS -4.67
Price-to-Earnings (P/E) Ratio -0.58
Price-to-Sales 1.87
Price-to-Book 2.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.98
Resistance 3 (R3) 3.00 2.93 2.94
Resistance 2 (R2) 2.93 2.85 2.92 2.92
Resistance 1 (R1) 2.81 2.81 2.78 2.79 2.91
Pivot Point 2.74 2.74 2.72 2.73 2.74
Support 1 (S1) 2.62 2.66 2.59 2.61 2.49
Support 2 (S2) 2.55 2.62 2.54 2.48
Support 3 (S3) 2.43 2.55 2.46
Support 4 (S4) 2.42